2,6-dihydroxy-trans-cinnamic acid | 1012326-86-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 2,6-dihydroxy-trans-cinnamic acid
• 英文别名: 2,6-Dihydroxy-trans-zimtsaeure；(E)-3-(2,6-dihydroxyphenyl)prop-2-enoic acid
• CAS: 1012326-86-1
• 化学式: C₉H₈O₄
• 分子量: 180.16
• InChiKey: WFVBGDQDYLTEJX-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 2,6-dihydroxy-trans-cinnamic acid 在 乙醚 作用下， 生成 methyl-2,5-dihydroxy-cinnamate
  参考文献：
  名称：

  Preparation and Reactions of o-Hydroxycinnamic Acids and Esters

  摘要：

  DOI：

  10.1021/ja01141a038
• 作为产物：
  描述：

  2,6-二羟基苯甲醛 在 吡啶 、 sodium hydrogensulfite 、 苯胺 、 sodium sulfite 作用下， 生成 2,6-dihydroxy-trans-cinnamic acid
  参考文献：
  名称：

  Preparation and Reactions of o-Hydroxycinnamic Acids and Esters

  摘要：

  DOI：

  10.1021/ja01141a038

文献信息

• [EN] LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM<br/>[FR] PROMÉDICAMENTS DE LEVORANOL ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：KEMPHARM INC

  公开号：WO2018191472A1

  公开（公告）日：2018-10-18

  The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and vitamin compounds chemically conjugated to levorphanol ((-)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.

  目前描述的技术提供了一种或多种羟基酸、聚乙二醇和维生素化合物与左旋吗啡醇((-)-17-甲基吗啡-3-醇)在化学上结合形成新型前药和左旋吗啡的组合物。
• Methylphenidate-Prodrugs, Processes of Making and Using the Same
  申请人：KemPharm, Inc.

  公开号：US20150266911A1

  公开（公告）日：2015-09-24

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  目前的技术是针对前药和组合物的，用于治疗包括甲基苯丙胺或甲基苯丙胺衍生物的至少与醇、胺、羧酸、硫醇或其衍生物结合的各种疾病和/或紊乱。在某些实施例中，这些结合物还包括至少一个连接剂。该技术还涉及合成甲基苯丙胺或甲基苯丙胺衍生物，结合至少一个醇、胺、羧酸、硫醇或其衍生物或其组合的方法。
• [EN] DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM<br/>[FR] PROMÉDICAMENTS DE DEXTRORPHANE ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：KEMPHARM INC

  公开号：WO2018191477A1

  公开（公告）日：2018-10-18

  The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and/or vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of dextrorphan.

  目前描述的技术提供了将一种或多种羟基酸、聚乙二醇和/或维生素化学共轭到右旋丙啡醇（(+)-17-甲基吗啡酮-3-醇）上，形成新型前药和右旋丙啡醇组合物的配方。
• PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID CONJUGATES AND PRODRUGS OF HYDROCODONE, METHOD OF MAKING AND USE THEREOF
  申请人：Mickle Travis

  公开号：US20110002991A1

  公开（公告）日：2011-01-06

  The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供苯乙酸、苯丙酸、苯丙烯酸、其盐、其衍生物或其化学结合到羟考酮（吗啡酮-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）以形成新型羟考酮的前药或组合物，其具有降低滥用羟考酮的潜力。该技术还提供了治疗患者的方法、药物配套和合成本技术结合物的方法。
• [EN] BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF<br/>[FR] CONJUGUÉS D'HYDROMORPHONE AVEC DE L'ACIDE BENZOÏQUE, DES DÉRIVÉS D'ACIDE BENZOÏQUE ET UN ACIDE HÉTÉROARYLCARBOXYLIQUE, PROMÉDICAMENTS, LEURS PROCÉDÉS DE FABRICATION ET LEURS UTILISATIONS
  申请人：KEMPHARM INC

  公开号：WO2013063204A1

  公开（公告）日：2013-05-02

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-α-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了含有芳基羧酸与羟吗啡（4,5-α-环氧-3-羟基-17-甲基吗啡-6-酮）化学共轭形成的新型前药/羟吗啡组合物的组合物。与未共轭的羟吗啡相比，本技术的羟吗啡前药具有减少副作用和滥用潜力的特点。本技术还提供了治疗患者的方法、药物配套工具和合成本技术共轭物的方法。